查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1794495

Empox Diagnostics全球市场

Mpox Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，Empox Diagnostics 全球市场规模将达到 22 亿美元

全球Empox诊断市场规模预计在2024年达到19亿美元，预计在分析期间（2024-2030年）将以2.7%的复合年增长率成长，到2030年将达到22亿美元。抗原检测测试是本报告分析的细分市场之一，预计其复合年增长率为2.1%，到分析期结束时将达到15亿美元。分子检测细分市场在分析期间内的复合年增长率预计为4.0%。

美国市场规模估计为 5.154 亿美元，中国市场预计复合年增长率为 5.0%

预计到2024年，美国Empox Diagnostics市场规模将达到5.154亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到4.261亿美元，在分析期间（2024-2030年）的复合年增长率为5.0%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为1.0%和2.0%。在欧洲，预计德国的复合年增长率为1.5%。

全球 Empox 诊断市场 - 主要趋势与驱动因素摘要

为什么人们对 Mpox 诊断解决方案重新产生了兴趣？

由于疾病发生模式的变化、全球监测活动的加强以及病例检测重点的转变，Empox Diagnostics 再次面临新的紧迫性。虽然天花过去主要在某些地区流行，但最近的跨境传播使及时诊断成为公共卫生优先事项。诊断在早期病例隔离、疫情追踪和接触者追踪中发挥核心作用。为了确保速度和准确性，诊断工具现在专注于基于病变的采样，而不是传统的血清学方法。

实验室检测主要依赖核酸扩增方法。这些技术可以检测皮肤病变和结痂是否有病毒DNA。从活动性病变采集检体时，检测准确率最高，这可以避免从血液检体中获得的病毒量可能存在的差异。尤其是在先进检测基础设施有限的地区，人们的关注点正转向能够快速、可靠且分散检测的工具。简化检体采集和缩短处理时间已成为新型诊断平台日益重要的设计要素。

为什么基于 PCR 的测试是目前实践的基准？

基于PCR的检测仍然是准确诊断mpox的基础。此方法灵敏度高、特异性，即使微量的病毒DNA也能侦测到。即时PCR检测是目前临床和公共卫生实验室中最可靠的平台。这些检测针对mpox病毒基因组的特定区域，可以区分不同的演化支并确认感染状态。目前有多种类型的PCR系统，从实验室分析仪到专为照护现场设计的携带式试剂盒设备。

为了提高可及性并缩短週转时间，新的分子诊断平台应运而生，其中一些平台能够在一小时内完成检测，从而支援疫情期间的快速决策。这些系统在需要快速对患者进行分诊和隔离时尤其有用。除了集中检测外，携带式分子诊断平台在方舱医院、边境入境点和行动医疗单位的应用也日益重要。这些平台的重点在于操作简便、技术培训要求低以及与现有医疗保健工作流程的兼容性。

快速抗原检测为何不符合诊断标准？

基于抗原的快速诊断检测方法尚未证实其在检测MPOX方面的可靠性。虽然部分方法已显示出较高的特异性，但灵敏度始终较低。大多数抗原检测方法难以检测到低病毒量，尤其是在感染早期和恢復期。它们无法检测无症状性或症状前病例，限制了其在监测和早期应对中的应用。这一限制限制了它们作为辅助筛检而非独立诊断手段的作用。由于这些局限性，卫生当局目前尚未核准这些检测方法用于临床。

为了弥补这些差距，开发工作正转向改进分子工具和新型检测技术。如今的诊断工具包括将分子检测与数位显示和远端监控功能相结合的工具。使用人工智慧辅助影像识别来评估病变照片的实验系统也正在接受评估。这些工具旨在为缺乏实验室设施的偏远地区提供诊断支援。然而，这些系统要想广泛应用，仍需要进一步的临床检验。

哪些因素推动了 Empox Diagnostics 市场的成长？

empox 诊断市场的成长受到多种因素的推动：疫情爆发的频率和地理分布不断增加，推动了对更快检测工具的需求；扩大即时检测 PCR 设备的使用，减少了农村和资源匮乏地区的检测延迟；将分子诊断纳入疫情应对试剂套件，可以更早地遏制基础设施增加对不需要大量实验室的携带式平台的设备，鼓励新进入疫情市场的投资，鼓励新参与企业市场。

日益重视分散式检查和移动诊断，这与开发中国家的公共卫生目标一致。将检测结果与监测资料库关联起来的数位健康工具的广泛应用也有助于有效率地管理疫情。由于与其他皮肤病和发烧疾病的症状重迭，鑑别诊断的需求日益增加，凸显了高度特异性检测的重要性。正在进行的产品核可和针对新型诊断平台紧急使用的监管指导，将继续支持产品创新和区域可及性。

部分

诊断检验（抗原检测检验、分子检验）；样本（尿液样本、全血样本、皮肤病检体样本）

受访公司范例

  • Abbott Laboratories
  • ACON Biotech（Hangzhou）
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid（Danaher Corporation）
  • Creative Biogene Inc.
  • DiaSorin SpA
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer（Alinity（TM）m MPXV assay）
  • Qiagen NV
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP37448

Global Mpox Diagnostics Market to Reach US$2.2 Billion by 2030

The global market for Mpox Diagnostics estimated at US$1.9 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.7% over the analysis period 2024-2030. Antigen Detection Test, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Molecular Test segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$515.4 Million While China is Forecast to Grow at 5.0% CAGR

The Mpox Diagnostics market in the U.S. is estimated at US$515.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$426.1 Million by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.5% CAGR.

Global Mpox Diagnostics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Diagnostic Solutions for Mpox?

Mpox diagnostics have gained renewed urgency due to changing patterns in disease outbreaks, increasing global surveillance efforts, and a shift in case detection priorities. Earlier, mpox was largely endemic to specific regions, but recent cross-border transmission has made timely diagnosis a public health priority. Diagnosis plays a central role in early case isolation, outbreak tracking, and contact tracing. To ensure speed and accuracy, diagnostic tools now focus on lesion-based sampling rather than traditional serological approaches.

Laboratory testing continues to rely primarily on nucleic acid amplification methods. These techniques detect the presence of viral DNA in skin lesions and scabs. Testing accuracy is highest when samples are collected from active lesions, avoiding potential variability in viral load from blood samples. Focus has shifted toward tools that allow rapid, reliable, and decentralized testing, particularly in regions with limited access to advanced laboratory infrastructure. Simplification of sample collection and faster processing times are increasingly important design factors for new diagnostic platforms.

What Makes PCR-Based Testing the Benchmark in Current Practice?

PCR-based testing remains the foundation for accurate mpox diagnosis. This method is highly sensitive and specific, detecting even low quantities of viral DNA. Real-time PCR assays are currently the most trusted platform used in clinical settings and public health laboratories. These tests target specific regions of the mpox virus genome, allowing differentiation between clades and confirmation of infection status. Several types of PCR systems exist, ranging from lab-based analyzers to portable, cartridge-based units designed for point-of-care use.

New molecular diagnostic platforms are emerging to improve access and reduce turnaround times. Some allow testing in under one hour, supporting faster decision-making in outbreak settings. These systems are particularly useful where rapid patient triage and isolation are needed. In addition to centralized testing, portable molecular platforms are gaining relevance for use in field hospitals, border entry points, and mobile health units. Emphasis remains on operational simplicity, minimal technical training, and compatibility with existing healthcare workflows.

Why Have Rapid Antigen Tests Failed to Meet Diagnostic Standards?

Antigen-based rapid diagnostic tests have not yet proven reliable for mpox detection. While some show high specificity, their sensitivity is consistently low. Most antigen tests struggle to detect lower viral loads, especially in early or healing stages of infection. Their inability to detect asymptomatic or pre-symptomatic cases limits their use in surveillance or early response. This limitation restricts their role to supplementary screening rather than standalone diagnosis. Due to these constraints, health authorities do not currently endorse these tests for clinical use.

In response to these gaps, development efforts are shifting toward improved molecular tools and novel detection technologies. Some diagnostic tools now combine molecular detection with digital readouts or remote monitoring features. Experimental systems using AI-assisted image recognition to assess lesion photographs are also being evaluated. These tools aim to support diagnosis in remote locations where laboratory facilities are unavailable. However, such systems require further clinical validation before they can be used widely.

What Factors Are Driving Growth in the Mpox Diagnostics Market?

Growth in the mpox diagnostics market is driven by several factors. Rising frequency of outbreaks and their geographic spread has increased the demand for faster detection tools. Expanded use of point-of-care PCR devices is helping reduce testing delays in rural and low-resource settings. Integration of molecular diagnostics into outbreak response kits is enabling early containment. Increased investment in portable platforms that operate without extensive laboratory infrastructure is encouraging market participation from new manufacturers.

Greater emphasis on decentralized testing and mobile diagnostics is aligning with public health goals in developing countries. Uptake of digital health tools that link test results with surveillance databases is also contributing to efficient outbreak management. Growing need for differential diagnosis due to overlapping symptoms with other skin or febrile illnesses is raising the importance of high-specificity assays. Ongoing product approvals and regulatory guidance for emergency use of new diagnostic platforms continue to support product innovation and regional accessibility.

SCOPE OF STUDY:

The report analyzes the Mpox Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnostic Test (Antigen Detection Test, Molecular Test); Sample (Urine Sample, Whole Blood Sample, Skin Lesion Specimen Sample)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Abbott Laboratories
  • ACON Biotech (Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMerieux
  • Cepheid (Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer (Alinity(TM) m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mpox Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Mpox Infections Spurs Demand for Rapid and Accurate Diagnostic Solutions
    • Government Surveillance Programs and Outbreak Preparedness Plans Drive Adoption of Diagnostic Testing
    • Technological Advancements in Point-of-Care Testing Strengthen Accessibility in Resource-Limited Settings
    • Integration of PCR and Isothermal Amplification Methods Propels Market for Molecular Mpox Diagnostics
    • Public Health Emergency Declarations Throw Spotlight on Fast-Tracking of Diagnostic Product Approvals
    • Expansion of Travel Screening and Quarantine Protocols Generates Demand for Portable Test Kits
    • Increasing Role of Central Laboratories in Outbreak Control Sustains Market for High-Throughput Systems
    • Demand for Cost-Effective Testing Solutions in Developing Nations Fuels Adoption of Lateral Flow Assays
    • Healthcare Worker Safety Protocols Drive Investment in Biosafe Sample Collection and Handling Tools
    • Growth in Zoonotic Disease Surveillance Expands Market Opportunity for Cross-Species Diagnostic Platforms
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mpox Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antigen Detection Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Whole Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Skin Lesion Specimen Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • JAPAN
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • CHINA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • EUROPE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • FRANCE
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • GERMANY
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • INDIA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Mpox Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Mpox Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
  • AFRICA
    • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030

IV. COMPETITION